Situation: A 29-year-old mother is 3 months postpartum and gives her baby only breast milk. She returns to her office job next week, where she works 8 hours a day, and she visits the health center for counseling before going back to work. The mother needs contraception now and will keep breastfeeding exclusively. She does not want a method she must remember every day, and she hopes to conceive again about a year from now, soon after she stops the method. She first asks about the 3-monthly injectable. Which recommendation fits her needs, and why?

Three needs must be met at once: safety during breastfeeding, no daily action, and a quick return of fertility. The 3-monthly injectable (DMPA) is safe while breastfeeding, but fertility may take many months to return after the last injection. The monthly combined injectable contains estrogen, which is not recommended while breastfeeding before 6 months, and progestin-only pills must be taken daily; the implant meets all three needs.

Clinical reasoning for postpartum contraception

This mother has three simultaneous needs: a method that is safe during exclusive breastfeeding, one that does not require daily action, and one from which she can transition to a planned pregnancy about a year later with minimal delay. The etonogestrel implant satisfies all three, whereas each alternative fails at least one requirement.

The 3-monthly injectable (DMPA) is compatible with breastfeeding but is the least favorable choice here because ovulation may remain suppressed for many months after the last injection. Return to fertility after DMPA discontinuation is often delayed, which conflicts with her stated goal of conceiving soon after stopping the method. The monthly combined injectable contains estrogen, which is generally avoided before 6 months postpartum in breastfeeding women because of concerns about milk supply. Progestin-only pills are safe for lactation and have a rapid return to fertility, but they require daily adherence, which she explicitly wants to avoid.

The implant is a long-acting reversible contraceptive (LARC) that provides highly effective protection without any daily or monthly action, and because it is progestin-only, it does not interfere with breast milk production. When the implant is removed, the contraceptive effect clears quickly, allowing a return to fertility within a short time. This aligns with her plan to conceive approximately one year from now.

Key point! In postpartum contraceptive counseling, the decision should be individualized around three axes: breastfeeding compatibility, user burden, and reversibility. The implant is the only option in this list that meets all three.

Method	Breastfeeding safety	User action required	Return to fertility
Implant	Safe (progestin-only)	None after insertion	Rapid after removal
3-monthly injectable (DMPA)	Safe	Injection every 3 months	Often delayed by several months
Monthly combined injectable	Not recommended before 6 months postpartum	Injection every month	Usually rapid
Progestin-only pills	Safe	Daily pill	Rapid

The evidence base reinforces this reasoning. Post-pregnancy contraception guidance emphasizes that most methods, including LARC, can be initiated safely in the postpartum period, but breastfeeding status modifies which methods are preferred ^[1][3]. Breastfeeding itself suppresses fertility, yet the return of ovulation is unpredictable, so contraception should not be delayed when pregnancy prevention is desired ^[2]. In addition, inconsistent postnatal contraceptive counseling is a recognized contributor to unintended pregnancy in the first postpartum year, underscoring the importance of matching method characteristics to the woman’s expressed preferences ^[4].

Watch out! Do not equate “safe while breastfeeding” with “best overall fit.” DMPA is safe during lactation, but its delayed return to fertility makes it a poor match for a woman who wants to conceive soon after discontinuation.